Three major classes of inotropic agents have been clinically evaluated in patients with left ventricular dysfunction: a) agents that increase the intracellular concentration of cyclic adenosine monophosphate by stimulating the beta-adrenergic receptor or inhibiting phosphodiesterase; b) drugs that increase the intracellular sodium concentration; c) the new calcium-sensitizing drugs. This review will focus on the newest drug for each of the above-mentioned classes of inotropic agents. Moreover, we present a new protocol which provides the use of levosimendan in patients with post-ischemic left ventricular dysfunction.
New positive inotropic agents in the treatment of left ventricular dysfunction / De Luca, L; Proietti, P; Palombaro, Gl; Battagliese, A; Celotto, A; Fedele, Francesco; BUCCIARELLI DUCCI, Chiara. - In: ITALIAN HEART JOURNAL. - ISSN 1129-471X. - STAMPA. - 5 Suppl 6:(2004), pp. 63s-67s.
New positive inotropic agents in the treatment of left ventricular dysfunction
FEDELE, Francesco;BUCCIARELLI DUCCI, CHIARA
2004
Abstract
Three major classes of inotropic agents have been clinically evaluated in patients with left ventricular dysfunction: a) agents that increase the intracellular concentration of cyclic adenosine monophosphate by stimulating the beta-adrenergic receptor or inhibiting phosphodiesterase; b) drugs that increase the intracellular sodium concentration; c) the new calcium-sensitizing drugs. This review will focus on the newest drug for each of the above-mentioned classes of inotropic agents. Moreover, we present a new protocol which provides the use of levosimendan in patients with post-ischemic left ventricular dysfunction.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
